Here's the rub, the manufacturing contractor has identified an inconsistency with one of the processes used in specification testing which is currently being rectified. Therefore IMO it's not the deoxymab but the testing process that's at fault. As they have identified it and are rectifying it I remain quietly confident. And yes, the patents could easily again IMO be worth billions. Check out the prices being paid for much lesser products.
Ann: Further update on PAT-DX1 GMP manufacturing run, page-47
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $3.425K | 1.058M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 29432066 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |